Advertisements

Квентиакс

Quick links to important sections

Квентиакс

Selected form

Advertisements
Advertisements

Treatment option: Bipolar Disorder, Schizophrenia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Квентиакс

Quick Facts

Property Description
Active ingredient Quetiapine (Quetiapine fumarate)
Form Film-coated tablets (IR and XR)
Pharmacological class Atypical Antipsychotic (Second-Generation)
General purpose Neurochemical stabilization of thought and emotion
Origin Synthetic compound
Rx Status Prescription-only medicine (Rx)

Defining Квентиакс: Classification and Composition

Квентиакс is a licensed, synthetic prescription-only (Rx) medication whose active ingredient is Quetiapine, a substance that belongs to the official class of atypical antipsychotics. The medication is administered via the oral route and is physically presented as film-coated tablets. Quetiapine, specifically a dibenzothiazepine derivative, is the sole active component in this product, typically utilized as the fumarate salt. As a single-ingredient product, it is manufactured in two primary pharmaceutical forms: an immediate-release (IR) formulation and an extended-release (XR) formulation. This distinction allows the delivery profile to be chosen based on the need for either rapid onset or a sustained effect.


Classification and Mechanism Overview

The pharmacological class of Квентиакс, the Second-Generation Antipsychotic (SGA) group, possesses a differentiated approach to influencing brain chemistry compared to older agents. This classification stems from its activity as a Serotonin-Dopamine Antagonist (SDA). The compound functions by performing concurrent, measured modulation of key neurotransmitter systems, specifically by blocking the activity of both dopamine (D2) and serotonin (5-HT2A) receptors. This dual-receptor antagonism is the foundation for its therapeutic effects. This characteristic means the medicine primarily acts to temper the flow of two critical chemical messengers in the brain.


General Purpose: Stabilizing Thought and Emotion

The overarching general purpose of this psychotropic agent is to support the rebalancing of dysregulated neurochemical activity within the central nervous system. By influencing the chemical messengers that control perception and mood—dopamine and serotonin—the medication is designed to normalize disruptive thought and emotional patterns. This action provides a broad therapeutic effect, aiming to support a more stable, grounded emotional and mental state for the patient in scenarios requiring careful neurochemical management.

Regulatory References

  1. Quetiapine
Advertisements

What side effects are possible with Квентиакс?

The safety profile of Quetiapine (Квентиакс) is documented by governmental regulatory authorities (such as the FDA and EMA), classifying potential effects by frequency and physiological system. This information details the formally recognized risks without providing clinical advice.


Adverse Reaction Classifications

Very Common and Common Effects

Side effects classified as Very Common (affecting more than 1 in 10 people) include somnolence (drowsiness), dizziness, dry mouth, and weight gain. Other very common effects involve the metabolism and blood systems, specifically elevated triglycerides and decreased haemoglobin. Effects classified as Common (up to 1 in 10 people) include orthostatic hypotension, tachycardia, constipation, increased appetite, hyperglycaemia, and the occurrence of extrapyramidal symptoms.

Serious Adverse Reactions

The label highlights serious, though typically uncommon, risks that warrant specific attention. These include the potential for Neuroleptic Malignant Syndrome (NMS), the movement disorder Tardive Dyskinesia (TD), and the possibility of severe metabolic changes that can lead to ketoacidosis. Vascular risks such as Venous Thromboembolism (VTE) and the risk of seizures are also documented.


Population and Time-Related Safety

Safety characteristics are distinct for certain groups, as noted in official documents. For elderly patients with dementia-related psychosis, there is a documented increased risk of death and cerebrovascular adverse reactions. Children and adolescents have a higher documented frequency of specific effects, including weight increase and elevated prolactin levels.

Official labeling associates certain effects, such as somnolence and orthostatic hypotension, with the initial dose-titration period, while the risk of Tardive Dyskinesia is associated with long-term exposure. The medication is contraindicated for co-administration with strong CYP3A4 inhibitors.

Advertisements

Overdose and Emergency Response

The official overdose profile for Квентиакс (Quetiapine) is defined by documented effects on the Central Nervous System (CNS) and the Cardiovascular System. Clinical manifestations of overdose commonly include drowsiness, somnolence, sedation, tachycardia (fast heartbeat), hypotension (low blood pressure), and potentially signs of anticholinergic effects like dry mouth.

Severe or life-threatening outcomes described in regulatory labeling include coma, respiratory depression, seizures, and serious cardiac risks such as QT interval prolongation and cardiac arrhythmias. Overdose severity is noted to be greater with massive ingestions and is also influenced by the presence of co-ingestants. Elderly patients and those with pre-existing cardiovascular or hepatic impairment are noted as being at increased risk for severe outcomes.

When overdose is suspected, immediate medical attention is required, and emergency services must be contacted immediately. The official regulatory management approach is symptomatic and supportive treatment. No specific antidote is known for Quetiapine overdose. Hospital-based care includes securing a clear airway, ensuring adequate ventilation, and mandatory continuous ECG monitoring until the patient achieves full recovery. In managing low blood pressure, official guidance states that pressor agents epinephrine and dopamine must be avoided.

Advertisements

Therapeutic Uses of Квентиакс

Квентиакс (Quetiapine) is used in situations involving certain distressing symptoms across conditions marked by severe instability in thought, mood, and activity levels. It plays a role in managing these disruptive symptomatic domains, is applied in contexts where additional support for symptom management is needed during acute phases, and supports functional stability. The medication is utilized in the management of Schizophrenia, Bipolar Disorder, and Major Depressive Disorder (MDD).

This medicine is considered relevant across domains where additional symptomatic support is needed, particularly in conditions characterized by periods of heightened symptoms.


Primary Therapeutic Focus

The medication is applied in addressing acute episodes involving core conditions such as Schizophrenia, Bipolar Disorder (including acute manic episodes and major depressive episodes), and as an adjunctive treatment in Major Depressive Disorder that requires additional symptomatic support. It helps address symptom clusters that may become intense or disruptive, covering manifestations like hallucinations, delusions, agitation, and extreme mood fluctuations.

It assists with maintaining functional stability during episodes and supports patients during phases of increased distress.


Quick Fact: Relief for Severe Mood and Thought Disturbances

Symptom Domain General Benefit Clinical Context
Psychotic Symptoms (Disorganized thought, delusions) May contribute to easing the overall symptom load Acute or chronic management of thought disorders
Affective Instability (Mania and Bipolar Depression) Is considered relevant for managing recurrent manifestations Long-term management and management of acute episodes
Depressive Manifestations (Treatment-resistant MDD) May assist with providing additional symptomatic support Adjunctive use in challenging symptomatic phases

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Квентиакс (Quetiapine) eligibility is strictly governed by regulatory classifications that define who may and who must not use the medicine.

Absolute Prohibitions

Use is formally contraindicated in patients with a known hypersensitivity to quetiapine or any formulation component. It is also prohibited for patients concurrently taking strong Cytochrome P450 3A4 (CYP3A4) inhibitors.

Furthermore, the medicine is not approved for the treatment of elderly patients with dementia-related psychosis due to documented risks, nor is it approved for children under 10 years of age for any indication.


Age- and Organ-Based Eligibility

Eligibility is established for adults across all approved conditions. For younger populations, the FDA approves specific use in adolescents (ages 10 and up for Bipolar Mania, 13 and up for Schizophrenia), though the EMA generally advises against use in patients under 18 years of age.

Patients with hepatic impairment require conditional use with a lower starting approach. Use in pregnancy is conditional, to be used only if the potential benefit justifies the potential risk, and breastfeeding is not recommended.


Conditional and Restricted Use

Use is restricted and requires caution in populations with a history of cardiovascular disease, cerebrovascular conditions, or those at risk for hypotension or QT prolongation.

Advertisements

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Квентиакс

Interaction Scope

Category Description
Medicinal product categories with documented interactions Strong CYP3A4 inhibitors, Potent CYP3A4 inducers, Centrally Acting Drugs, Antihypertensive Agents, Anticholinergic Drugs, Levodopa and Dopamine Agonists.
Specific interacting medicines (if explicitly listed) Dronedarone (Contraindicated), Ketoconazole, Ritonavir, Phenytoin, Rifampin.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction (reduced or increased clearance of Quetiapine via CYP3A4 metabolism). Pharmacodynamic interaction (additive effects, such as CNS depression, or antagonistic effects).
Timing-based interaction rules (if applicable) The Extended-Release (XR) formulation must be taken without food or with a light meal due to food-related increases in drug absorption.
Population-specific interaction notes (if applicable) Hepatic Impairment: Patients with impaired liver function require a specific adjustment strategy due to reduced clearance.
Interaction-related restrictions Contraindicated with Dronedarone. Grapefruit Juice and alcohol consumption are restricted.

Interaction Classifications (High-Level)

Classification Description
Interaction severity classification (as defined in official documents) Contraindicated Combination (Dronedarone). Clinically Significant Interactions requiring formal change (CYP3A4 agents). Use with Caution (CNS-acting agents).
Regulatory basis (EMA / FDA / etc.) Based on official governmental Prescribing Information.
Interaction-context constraints (as defined in official documents) The absorption profile of the XR formulation is constrained by the presence of food, mandating specific administration timing.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Dronedarone is formally contraindicated by regulatory bodies due to documented risk of elevated Quetiapine exposure and cumulative cardiac risk.
  • Strong CYP3A4 Inhibitors significantly decrease the clearance of Quetiapine, resulting in a required reduction in dose to prevent high plasma concentrations.
  • Potent CYP3A4 Inducers significantly increase the clearance of Quetiapine, necessitating a substantial increase in dose for continued co-administration.
  • Concomitant use with Centrally Acting Drugs (including alcohol) increases the risk of additive CNS depression.

Connection to the overall interaction profile (2–4 sentences):

The regulatory documentation defines the product's interaction structure primarily through its dependence on the CYP3A4 enzyme, which is the basis for clinically significant pharmacokinetic interactions with inhibitors and inducers. This metabolic dependence leads directly to required modifications and the contraindication of Dronedarone. Furthermore, the profile highlights pharmacodynamic interactions that require caution with agents that share overlapping actions.

Advertisements

Mechanism of Action

Targeting Key Neurotransmitter Receptors

Квентиакс (Quetiapine) primarily acts by binding to and blocking specific neurotransmitter receptors in the central nervous system. Its main interaction is as an antagonist at Dopamine (D2) and Serotonin (5-HT2A) receptor subtypes. This molecular engagement prevents these receptors from being fully activated by their natural signaling molecules, thereby initiating the drug's mechanism of action.


Modulating Signaling Pathways

By engaging these receptors, the drug modulates complex neurotransmitter pathways associated with heightened or dysregulated activity. This targeted interaction achieves the regulation of overactive physiological responses by adjusting signaling dynamics within critical neural circuits, resulting in altered signal transduction. This alteration occurs within systems where specific transmitters dominate and is used to influence core mechanisms underlying the drug's effect profile.


Downstream Physiological Adjustments

Interference at the receptor level initiates downstream molecular cascades that ultimately influence central regulatory systems. This mechanistic adjustment modifies the excitation level of neural activity and reduces the downstream effect of excessive mediator activity, thereby determining the resulting physiological profile of the compound.

Advertisements

Dosage and Administration Information

How to Use Квентиакс

The use of Квентиакс (Quetiapine) follows administration patterns specific to its two available forms, both taken via the oral route. The medication is available as an Immediate-Release (IR) tablet and an Extended-Release (XR) tablet.

Dosing and Frequency

Administration protocols are dependent on the formulation and indication. The IR form is often administered twice daily for certain indications, while the XR form is administered once daily, typically in the evening. Treatment is initiated using a rapid titration schedule, where the dose is increased over several days to reach the established maintenance dose range. These ranges can extend up to 800 mg per day for specific conditions.

Administration Conditions and Special Rules

Feature Administration Guidelines
IR Tablets May be taken with or without food.
XR Tablets Must be taken without food or with a light meal (e.g., approximately 300 calories).
Tablet Integrity XR tablets must be swallowed whole and must not be split, chewed, or crushed.
Missed Dose If a dose is missed, it should be skipped if it is almost time for the next scheduled dose, and doses should not be doubled.

Population-Specific Adjustments

A lower starting dose and a slower titration rate are utilized for older adults (geriatric patients) and individuals with known hepatic impairment. These adjustments are procedural steps standard for the application of the medication's therapeutic protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Квентиакс

Evidence for Use in Schizophrenia

Research explored quetiapine for schizophrenia using short-term, placebo-controlled Randomized Controlled Trials (RCTs) in adults and adolescents with acute symptoms. These studies monitored changes in symptom severity using tools like the PANSS (Positive and Negative Syndrome Scale). For long-term outcomes, maintenance trials explored the prevention of symptoms returning in stable patients. Follow-up durations were limited in many acute studies, and there is limited information for long-term functional recovery.

Evidence for Use in Bipolar Disorder

Research explored its use across the different phases of bipolar disorder. For acute mania, studies were evaluated in adults and adolescents using short-term RCTs that monitored changes with the YMRS (Young Mania Rating Scale). For acute bipolar depression, research explored monotherapy use in adults with Bipolar I or II, monitoring changes with the MADRS (Montgomery-Åsberg Depression Rating Scale). Comparative evidence against other treatments was lacking in certain study designs.

Evidence for Adjunctive Use in Major Depressive Disorder (MDD)

Research examined quetiapine as an add-on treatment in adults with MDD who demonstrated an inadequate response to standard antidepressant therapy. These were short-term, placebo-controlled RCTs that reported how symptoms evolved in combination with the existing antidepressant. Findings were mixed across some major trials.

Key Gaps and Uncertainties in the Research Record

The bulk of the research was observed in adults. Data for certain groups, such as children, pregnant populations, and those with complex comorbidities, remain insufficient. Overall, follow-up durations were limited in many acute studies, and long-term outcomes are not fully established. Evidence quality varies across studies, and results apply only to the populations studied.

Key Studies & References

  1. Quetiapine for acute mania in bipolar disorder (Database of Abstracts of Reviews of Effects - DARE) - Addressing YMRS outcomes and adjunctive trials.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Квентиакс (FAQ)


Q: What happens if I forget to take a dose of Квентиакс?

Official guidance states that a missed dose should be skipped if it is almost time for the next scheduled dose. It is important that doses are not doubled to compensate for the missed one. Following the prescribed schedule is important for maintaining consistent treatment.

Q: Are there any specific foods or drinks, like grapefruit juice, that interact with Квентиакс?

Yes, grapefruit juice is restricted because it contains strong inhibitors of an enzyme called CYP3A4. This enzyme is crucial for clearing the medicine from your body. Consuming grapefruit juice can significantly increase the level of the medicine in the blood, which may lead to an increased risk of adverse effects.

Q: Does Квентиакс affect mental clarity or ability to concentrate?

Official product information notes that the medicine is associated with common effects like somnolence (drowsiness) and dizziness. These effects may temporarily impair a person's ability to perform tasks requiring high mental alertness or concentration.

Q: Is it required to have routine eye exams while using Квентиакс?

A routine eye examination is officially recommended according to product documentation. Lens changes, such as the development of cataracts, have been observed in patients during long-term treatment. Regulatory documents recommend an examination when starting the medicine and at 6-month intervals during chronic use.

Q: What is the risk of developing cataracts while taking Квентиакс?

The official documentation notes that lens changes, which can include the formation of cataracts, have been observed in some patients treated with this medication for an extended period. This risk is why routine eye monitoring is often advised as part of the official monitoring requirements.

Q: How common are changes in menstrual cycles while taking Квентиакс?

The medication may cause an increased level of the hormone prolactin in the blood. High prolactin levels are associated with various side effects, including irregular or absent menstrual periods. Changes such as these are typically discussed with the prescribing physician.

Q: Does the initial side effect of sedation usually wear off with continued use?

Official labeling suggests that side effects such as somnolence (drowsiness) and orthostatic hypotension (dizziness when standing up) are associated primarily with the initial dose-titration period. The frequency of these effects is associated with the initial dose-titration period.

Q: How long does it usually take to feel the initial effects of Квентиакс?

While some effects, particularly on sleep, may be noticed sooner, authoritative medical sources indicate that the full therapeutic effect of the medicine may take two to three months to be fully established. Maintaining treatment consistency is generally necessary to realize the medicine's full therapeutic effect.

Q: How long does Квентиакс typically stay in a person's system?

The active ingredient is metabolized (broken down) and cleared from the body with a mean terminal half-life of approximately 6 hours. This indicates how long it takes for half of the medicine to be processed. The body typically achieves stable, or 'steady-state,' concentrations within about two days.

Q: Can Квентиакс be taken with anti-anxiety medications (like benzodiazepines)?

The use of this medicine in combination with other Centrally Acting Drugs, such as anti-anxiety medications, requires caution. Official documents note that this combination increases the risk of additive CNS depression, which can lead to increased drowsiness and impaired alertness.

Q: Can the use of Квентиакс lead to high prolactin levels?

Yes, regulatory documents indicate that the use of this medication may lead to an increased level of the hormone prolactin in the blood, a condition known as hyperprolactinemia. This hormonal change may be associated with various side effects.

Q: Can Квентиакс cause increased sleepiness or drowsiness during the day?

Yes, the product information classifies somnolence (drowsiness) as a Very Common adverse reaction, meaning it is reported in more than 1 in 10 people. This drowsiness can occur during the day and can affect daily activities.

Q: Why might a patient feel dizzy or lightheaded when standing up while taking Квентиакс?

The feeling of dizziness or lightheadedness when standing up is associated with orthostatic hypotension. This is a sudden drop in blood pressure that can occur when changing position. It is associated with the drug's activity on certain receptors that influence the circulatory system.

Q: Is it safe to drive or operate machinery while adjusting to Квентиакс?

Due to the potential for somnolence and other effects on the nervous system, official patient counseling information advises caution. Patients should refrain from operating hazardous machinery, including automobiles, until they are reasonably certain the medicine does not affect their alertness or coordination.

Q: What kind of monitoring is typically required when starting Квентиакс?

Official guidance mandates routine clinical monitoring to check for potential metabolic changes. This monitoring typically includes testing for fasting blood lipid levels, blood glucose levels (to check for high blood sugar), and tracking changes in weight.

Q: Can Квентиакс affect a person's sex drive or sexual function?

The documented potential to cause high prolactin levels is a factor that may be associated with changes in sexual function or sex drive. Concerns regarding changes in sexual function are generally discussed with a healthcare provider.

Q: What does official research say about the use of Квентиакс in adolescents with schizophrenia?

Official documents confirm that clinical trials have been conducted to evaluate its use in adolescents with schizophrenia. The overall effectiveness and safety profile observed in this younger age group are consistent with the established labeling for the medicine.

Q: Is it true that Квентиакс can cause trouble swallowing?

Difficulty swallowing, medically known as dysphagia, has been reported in the scientific literature regarding second-generation antipsychotic agents. This is possibly due to the drug's influence on the central nervous system that can affect muscle control.

Q: What are the signs of a severe allergic reaction to Квентиакс?

Signs of a severe allergic reaction may include swelling of the face, lips, mouth, tongue, or throat, or experiencing trouble breathing or wheezing. A severe skin rash or hives may also occur, which are signs of a severe hypersensitivity reaction.

Q: Does taking Квентиакс increase the risk of developing diabetes?

Yes, the product labeling carries a formal warning for Hyperglycemia and Diabetes Mellitus (DM). The risk for developing diabetes is associated with this class of medicine, and monitoring of blood sugar levels is recommended.

Q: What is the connection between Квентиакс and restlessness or difficulty sitting still?

The drug is associated with Extrapyramidal Symptoms ( EPS), which include a condition called Akathisia. Akathisia is characterized by a subjective feeling of restlessness or an objective difficulty with sitting still.

Q: Are there any known interactions between Квентиакс and herbal supplements, like St. John's Wort?

Yes, the herbal supplement St. John's Wort is listed in regulatory documents as an agent that is a strong inducer of the CYP3A4 enzyme. This effect can cause the medicine to be processed and eliminated from the body much faster, potentially making it less effective.

Q: Can Квентиакс cause low blood pressure, and what are the symptoms?

The medicine can cause orthostatic hypotension (low blood pressure upon standing). Symptoms may include dizziness, feeling lightheaded, or fainting. This effect is often associated with the process of establishing the appropriate dosage.

Q: Why is monitoring blood pressure necessary while taking Квентиакс?

Monitoring blood pressure is required because of the risk of orthostatic hypotension, which is a sudden drop in blood pressure when changing from sitting or lying down to a standing position. This condition can lead to dizziness and falls.

Q: Does Квентиакс cause problems with body temperature regulation?

The risk of Neuroleptic Malignant Syndrome ( NMS) is documented in official warnings. NMS is a rare but serious condition that can involve signs of autonomic instability, including hyperpyrexia (high fever), which indicates a potential problem with the body's ability to regulate temperature.

Q: Is it possible for Квентиакс to affect the heart or heart rhythm?

Yes, the product labeling includes a warning for the possibility of QT interval prolongation, which is an effect on the heart's electrical rhythm. This effect can lead to the risk of related serious cardiac events, and caution should be exercised according to official prescribing information.

Q: Is the use of Квентиакс restricted by any specific condition like glaucoma?

The medicine has documented anticholinergic properties, which means it may lead to an additive effect if taken with other anticholinergic drugs. Official caution is therefore required for patients with pre-existing conditions sensitive to anticholinergic effects, such as a risk for increased pressure in the eye.

Advertisements

How should Квентиакс be stored and disposed of?

Storage Conditions

Quentiax (quetiapine) does not require any special temperature storage conditions for the unopened product, allowing for room temperature storage.

  • Child Safety: The medicine must be kept out of the sight and reach of children.
  • Container: The product should be stored in the original package to protect it from light and moisture, and must not be used after the expiry date.

Disposal Instructions

Medicines should not be disposed of via wastewater or household waste to protect the environment. Patients must ask a pharmacist how to dispose of medicines no longer required in accordance with local pharmaceutical waste regulations. The disposal procedure ensures proper handling of unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Квентиакс found in:

A-Z Index: